KOL Perspectives: Update on Novel Candidates in Development for Lupus
- GDHC048SP
- Pages: 35
- May 2018
- Total Views:1139
- Region : Global
- GlobalData
- Market Research Report
Details
KOL Perspectives: Update on Novel Candidates in Development for Lupus
Summary
This KOL Insight briefing provides an update on novel candidates in development for Lupus.
The briefing includes analysis of KOL opinion on the following topic areas-
- Atacicept's efficacy data in SLE
- Atacicept's flare data in SLE
- Patients most suitable for atacicept treatment
- Targeting the IgE pathway in lupus
- Omalizumab'sefficacy data in SLE
- Omalizumab'ssafety data in SLE
- Lupuzor's Phase III efficacy data
- Impact of lupuzor's Phase III data on existing opinion of lupuzor
- Lupuzor's Phase III safety data in SLE
- Anticipated future use of lupuzor in clinical practice
Key Highlights
- Most KOLs had a positive opinion of atacicept's efficacy in SLE despite failure to achieve its primary endpoint of SRI-4 in the ITT population
- KOL opinions were divided in terms of targeting the IgE pathway in lupus, with some unaware of any scientific rationale behind it
- Most KOLs were disappointed by lupuzor's Phase III efficacy data but were not surprised by the high placebo response rate observed in the trial.
Scope
- The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: Five Europe-based & fuve US-based
- Interviews performed in Q2 2018
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Reasons to buy
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Novel Candidates in Development for Lupus"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Table Of Content
Scope
Table of Contents
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Lupus, Atacicept, IgE, Omalizumab, Lupuzor
Companies
EMD Serono
Novartis
Roche
Genentech
ImmuPharma
Company Profile
Company Profile Title
KOL Perspectives: Update on Novel Candidates in Development for Lupus
Summary
This KOL Insight briefing provides an update on novel candidates in development for Lupus.
The briefing includes analysis of KOL opinion on the following topic areas-
- Atacicept's efficacy data in SLE
- Atacicept's flare data in SLE
- Patients most suitable for atacicept treatment
- Targeting the IgE pathway in lupus
- Omalizumab'sefficacy data in SLE
- Omalizumab'ssafety data in SLE
- Lupuzor's Phase III efficacy data
- Impact of lupuzor's Phase III data on existing opinion of lupuzor
- Lupuzor's Phase III safety data in SLE
- Anticipated future use of lupuzor in clinical practice
Key Highlights
- Most KOLs had a positive opinion of atacicept's efficacy in SLE despite failure to achieve its primary endpoint of SRI-4 in the ITT population
- KOL opinions were divided in terms of targeting the IgE pathway in lupus, with some unaware of any scientific rationale behind it
- Most KOLs were disappointed by lupuzor's Phase III efficacy data but were not surprised by the high placebo response rate observed in the trial.
Scope
- The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: Five Europe-based & fuve US-based
- Interviews performed in Q2 2018
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Reasons to buy
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Novel Candidates in Development for Lupus"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Scope
Table of Contents
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Lupus, Atacicept, IgE, Omalizumab, Lupuzor
Companies
EMD Serono
Novartis
Roche
Genentech
ImmuPharma
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020